Key Differentiators

Orally active anti-obesity drug vs injection type GLP-1 mimetics • Target in MoA: FFA4 vs GLP-1R (indirect action on GI-> reduction of side effects) • Long-term administration by safety of small molecule • Accessibility(patient compliance) • Competitive price by reduced manufacturing cost

Completed efficacy, ADME, and toxicity validation through R&D projects

ADME, and toxicity • Liver metabolism stability: Human liver T1/2: 0.25 hr • Plasma stability: Predicted as a stable chemical in plasma • Cardiac toxicity: hERG inhibition Low possibility • Genetic toxicity: Low probability of mutagenesis induction • Caco-2 cell permeability: 0.99

Global anti-obesity market grows fast not only for simple beauty but also as a key solution for chronic metabolic diseases GLP-1 mimetics Successful as obesity remedy

Market size of anti-obesity therapeutics 7.72 billion$ in 2030 (CAGR 31.6%)